Participant flow

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · Source last updated 2020-11-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Akt inhibitor MK2206 200 mg orally once a week, repeats every 28 days for up to 12 courses.

   id

   FG000

   title

   Akt Inhibitor MK2206

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         60

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         59

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Recruitment Period: December 10, 2010 to February 20, 2013. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice